Setting the Benchmark for Efficacy & Safety in CAR-T Therapy
- Learnings on dual CAR-T design, why targeting CD20xCD22 simultaneously
- Rationale for NHL indication
- Present the eti-cel preliminary data
The Industry's Leading, Deeply Technical Flagship Cell Therapy Forum
September 15-17 2026 I Boston, MA
September 15-17 2026 I Boston, MA